Brief: Ambu Expands Neurology Portfolio In U.S. And Europe
20/08/2026 08:23
BRIEF-Ambu Expands Neurology Portfolio In U.S. And Europe Aug 20 (Reuters) - Ambu A/S AMBUb.CO:
EXPANDS NEUROLOGY PORTFOLIO IN NORTH AMERICA AND EUROPE
GETS 510(K) CLEARANCE FROM FDA AND EUROPEAN REGULATORY CLEARANCE (CE MARKING) FOR ITS NEW AMBU NEUROLINE CUP MRI/CT SOLUTION
TO LAUNCH NEW SOLUTION IN BOTH THE U.S. AND EUROPE IN THE FALL OF 2026
Further company coverage: [AMBUb.CO]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ambu A/S
See all newsBrief: Ambu Says Two Bronchoscopes Get FDA Clearance, CE Mark For Use In Pediatric Airway Procedures
Brief: Ambu Obtains Regulatory Clearances For Expanded GI Indication
UBS turns cautious on Ambu's targets, cuts to 'neutral'
Brief: Ambu Acquires TIMS Medical To Advance Endointelligence
Brief: Ambu Reports Q3 EBIT DKK 221 Mln